Molecular Partners AG - ADR

The momentum for this stock is not very good. Molecular Partners AG - ADR is not a good value stock. Molecular Partners AG - ADR is not very popular among insiders. Tradey thinks it is not wise to invest in Molecular Partners AG - ADR.

News

Molecular Partners AG (ADR) trading resumes

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Molecular Partners price target raised by CHF 0.80 at JPMorgan

Molecular Partners rethinks tetra-specific dosing after seeing 'suboptimal exposure' in cancer trial

FierceBiotech.com - Biotech Molecular Partners rethinks tetra-specific dosing after seeing 'suboptimal exposure' in cancer trial\nntaylor\nTue, 08/27/2024 - 10:01...\n more…

Molecular Partners reports 1H results

SeekingAlpha.com: All News Molecular Partners reports 1H 2024 financials with GAAP EPS of -CHF0.80 and total revenues of CHF4.3M, expecting expenses of CHF65-75M in 2024.\n more…

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

Globe Newswire First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial clinical data expected in 2025 Strategic collaboration agreement signed with...\n more…

Molecular Partners: A Speculative Bet On Innovative DARPin Technology

SeekingAlpha Molecular Partners: A Speculative Bet On Innovative DARPin Technology...\n more…